BREVITAL SODIUM (methohexital sodium) by Pfizer is clinical pharmacology compared with thiamylal and thiopental, methohexital is at least twice as potent on a weight basis, and its duration of action is only about half as long. First approved in 1960.
Drug data last refreshed 20h ago · AI intelligence enriched Yesterday
Brevital Sodium (methohexital sodium) is a rapid-acting barbiturate anesthetic administered intravenously, intramuscularly, or rectally for induction and short-duration anesthesia. It is approximately twice as potent as thiamylal and thiopental with a duration of action only half as long, making it suitable for brief procedures. The drug rapidly crosses the blood-brain barrier, inducing sleep within 30 seconds intravenously or 2–15 minutes via other routes.
This legacy injectable anesthetic is approaching loss of exclusivity with low commercial momentum, suggesting a small defensive team focused on operational efficiency rather than growth.
CLINICAL PHARMACOLOGY Compared with thiamylal and thiopental, methohexital is at least twice as potent on a weight basis, and its duration of action is only about half as long. Although the metabolic fate of methohexital in the body is not clear, the drug does not appear to concentrate in fat…
Worked on BREVITAL SODIUM at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Brevital Sodium offers limited career growth given its LOE-approaching status and zero linked job openings; roles are defensive and operationally focused on maintaining existing market position. This is a suitable assignment for specialists seeking stability in a legacy product rather than launch or innovation-driven career momentum.